• Molecular NameTemozolomide
  • SynonymMethazolastone; Temozolamide; Temozolodida [Spanish]; temozolomide; Temozolomidum [Latin]
  • Weight194.154
  • Drugbank_IDDB00853
  • ACS_NO85622-93-1
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-0.89
  • pkaN/A
  • LogD (pH=7, predicted)-0.89
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.84
  • LogSw (predicted, AB/LogsW2.0)15.18
  • Sw (mg/ml) (predicted, ACD/Labs)6.74
  • No.of HBond Donors3
  • No.of HBond Acceptors8
  • No.of Rotatable Bonds1
  • TPSA116.8
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyAn oral alkylating agent which can be used for the treatment of Grade IV astrocytoma -- an aggressive brain tumor, also known as glioblastoma multiforme.
  • Absorption_value100.0
  • Absorption (description)Rapid and complete absorption in the gastrointestinal tract
  • Caco_2N/A
  • Bioavailability96.0
  • Protein binding15.0
  • Volume of distribution (VD)0.4 L/kg; 17 L/m2
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmSpontaneously hydrolyzed at physiologic pH to the active species, 3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC) and to temozolomide acid metabolite.
  • Half life1.8 h (temozolomide); 2.5 min (MTIC).
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityDuring the concomitant phase (Temozolomide + radiotherapy) of the treatment of newly diagnosed glioblastoma multiforme, adverse events including thrombocytopenia, nausea, vomiting, anorexia and constipation, were more frequent in the Temozolomide + radiotherapy arm than in the radiotherapy arm.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A